Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tevogen Bio Holdings Inc (TVGNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: TVGNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 219335 | Beta -1.05 | 52 Weeks Range 0.01 - 0.15 | Updated Date 02/26/2025 |
52 Weeks Range 0.01 - 0.15 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -542.18% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13914824 |
Shares Outstanding - | Shares Floating 13914824 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tevogen Bio Holdings Inc
Company Overview
History and Background
Tevogen Bio Holdings Inc. is a biotechnology company focused on developing immunotherapies for cancer and viral infections. Details on its founding year and specific milestones are not widely available in public sources. The company has focused on developing T-cell based immunotherapies.
Core Business Areas
- T-Cell Immunotherapies: Development and commercialization of allogeneic T-cell immunotherapies for cancer and viral infections.
Leadership and Structure
Information on Tevogen Bio Holdings Inc.'s specific leadership team and organizational structure is limited in readily available public sources. Generally, a biotechnology company has a CEO, CSO, and heads of R&D, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- TVGN-489: An allogeneic cytotoxic CD8+ T lymphocyte (CTL) product designed to target multiple tumor-associated antigens (TAAs) for solid tumors. Market share data is not publicly available. Competitors include companies developing similar T-cell therapies such as Adaptimmune and Iovance Biotherapeutics.
- TVGN-789: An allogeneic cytotoxic CD8+ T lymphocyte (CTL) product to target Cytomegalovirus (CMV), a common viral infection. Market share data is not publicly available. Competitors include companies such as AlloVir.
Market Dynamics
Industry Overview
The immunotherapy market is experiencing rapid growth, driven by advancements in cell and gene therapies and increasing prevalence of cancer and infectious diseases.
Positioning
Tevogen Bio Holdings Inc. is positioned as a developer of allogeneic T-cell therapies. Its competitive advantage may lie in its proprietary technology and approach to targeting tumor-associated antigens and viral infections.
Total Addressable Market (TAM)
The TAM for cell and gene therapies is projected to reach tens of billions of dollars. Tevogen Bio Holdings Inc. is positioned to capture a share of this market with its T-cell therapy pipeline. The exact figure is difficult to determine as the market is constantly evolving
Upturn SWOT Analysis
Strengths
- Proprietary allogeneic T-cell therapy platform
- Targeting of multiple tumor-associated antigens and viral targets
- Potential for off-the-shelf therapy
- Potentially lower manufacturing costs compared to autologous therapies
Weaknesses
- Limited clinical data available
- Relatively small company size
- Reliance on raising capital
- Risk associated with clinical trials and regulatory approval
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to additional cancer and viral targets
- Positive clinical trial results
- Advancements in manufacturing processes
- Market growth in cell and gene therapies
Threats
- Competition from other immunotherapy companies
- Regulatory hurdles and delays
- Clinical trial failures
- Reimbursement challenges
- Economic downturn impacting biotech funding
Competitors and Market Share
Key Competitors
- ADAP
- IOVA
- ALVR
Competitive Landscape
Tevogen Bio Holdings Inc. faces intense competition in the immunotherapy market. Its advantages depend on the efficacy and safety of its T-cell therapies compared to competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's stage of development and limited public information.
Future Projections: Future growth projections are speculative and depend on the success of clinical trials and regulatory approvals. Analyst estimates are not widely available.
Recent Initiatives: Recent initiatives may include advancing its lead T-cell therapy candidates through clinical trials.
Summary
Tevogen Bio Holdings Inc. is a biotechnology company developing novel T-cell immunotherapies with potential in cancer and viral infections. As a smaller company, it faces risks related to clinical trials, regulatory approval, and funding. Success hinges on demonstrating efficacy and safety in its lead candidates. Opportunities exist through partnerships and pipeline expansion, but competition in the immunotherapy space is intense.
Similar Companies
- ADAP
- IOVA
- ALVR
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (if available)
- Industry reports
- Press releases
Disclaimers:
This analysis is based on limited publicly available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor and conducting thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tevogen Bio Holdings Inc
Exchange NASDAQ | Headquaters Warren, NJ, United States | ||
IPO Launch date 2022-01-03 | Co-Founder, CEO & Chairman Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://tevogen.com |
Full time employees - | Website https://tevogen.com | ||
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.